Highlights

  • Wall Street Zen upgraded Lucid Diagnostics from "sell" to "hold" on Tuesday.
  • Analysts’ price targets range from USD 2.50 to USD 8.00 across multiple firms.
  • MarketBeat data indicates a consensus "Moderate Buy" with an average target of USD 3.70.

Equities research analysts have recently adjusted their ratings for Lucid Diagnostics (NASDAQ:LUCD). Wall Street Zen upgraded the stock from a "sell" rating to a "hold" rating in a report released Tuesday. Needham & Company LLC maintained a "buy" rating and set a USD 3.00 price target on August 13th. BTIG Research increased its target price from USD 2.00 to USD 2.50 and retained a "buy" rating on September 5th.

Weiss Ratings reiterated a "sell (d-)" rating on September 27th. Ascendiant Capital Markets raised its target from USD 7.75 to USD 8.00 and continued to assign a "buy" rating on October 6th. In total, five analysts have given a Buy rating, while one analyst assigned a Sell rating.

Consensus Overview
According to MarketBeat.com, Lucid Diagnostics carries a consensus rating of "Moderate Buy" with an average price target of USD 3.70. This range reflects differing analyst assessments and updated price objectives over recent months.

Company Profile
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The firm develops solutions for patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer, including highly lethal esophageal adenocarcinoma. The company’s diagnostic technologies aim to provide clinical insight for early identification of high-risk patients.

Recent Activity Summary
Recent analyst reports for LUCD focus on target price adjustments and rating revisions rather than new operational developments. The stock’s rating history includes a mix of Buy, Hold, and Sell opinions, indicating varied analyst perspectives on its market potential and valuation metrics.